Navigation Links
Venaxis to Present at 25th Annual ROTH Conference
Date:3/11/2013

as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for APPY1 required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from APPY1 at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AspenBio Pharma Changes Company Name to Venaxis, Inc.
2. Venaxis to Present at 2013 BIO CEO and Investor Conference
3. Venaxis Presentation Rescheduled for 2013 BIO CEO and Investor Conference
4. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
5. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
7. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
8. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
10. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
11. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Valeant Pharmaceuticals International, Inc. (NYSE: ... company,s Bridgewater, New Jersey location ... Drug Administration (FDA) relating to an inspection in June ... Aesthetic injectable, which was divested to Galderma S.A. in ... Valeant,s contract manufacturers (rather than Valeant,s own internal manufacturing) ...
(Date:9/30/2014)... MOUNTAIN VIEW, Calif. , Sept. 30, 2014 /PRNewswire/ ... today, which integrates with HealthKit in iOS 8 and ... with their doctors. The app harnesses native iOS technologies ... patients to maintain a robust connection with their doctors ... wearable health devices and the data they collect is ...
(Date:9/30/2014)... Sept. 30, 2014  Based on its recent ... & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), ... 2014 North American Frost & Sullivan Award for ... along with a focus on innovation and improving ... in tissue-based cancer diagnostic solutions for patients worldwide. ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4
... Neb., May 15 Creighton Medical Laboratories, based at ... announced today that it has become the first clinical ... testing method for cancer. The method, called SNP array ... to study cancer for several years. However, Creighton Medical ...
... Case Demonstrating RenalGuard To Be PresentedFRANKLIN, Mass., May ... PLCSF), a company focused on innovative cardiac and ... will demonstrate its RenalGuard System(TM) at EuroPCR, the ... Cardiovascular Interventions (EAPCI), May 19-22, 2009, in Barcelona, ...
Cached Medicine Technology:Creighton Medical Laboratories First to Offer New Cancer Test 2Creighton Medical Laboratories First to Offer New Cancer Test 3PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 2PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 3PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 4
(Date:9/30/2014)... and cardiac muscles contain few stem cells, heart ... heart attack. Now Tel Aviv University researchers are ... tissue engineering. , Dr. Tal Dvir and his ... Biotechnology, Department of Materials Science and Engineering, and ... sophisticated micro- and nanotechnological tools ranging in ...
(Date:9/30/2014)... 2014 A new report launched today by ... Longitudinal Study on Ageing) conducted by academics from ... Dublin, Ireland, has highlighted the serious, complex and ... disability population. , The IDS-TILDA study is the ... the only one in the world with the ...
(Date:9/30/2014)... MyServer2Go.com made an announcement recently that ... this year for its quality VPS solution, reliable support ... MyServer2Go.com is a professional and targeted website which reviewed ... announcement will help webmasters find the best VPS hosting ... http://www.arvixe.com ) is one of the fastest-growing and most ...
(Date:9/30/2014)... Wellington, New Zealand (PRWEB) September 30, 2014 ... offers the potential to improve breast cancer risk ... risk, according to a study published in Breast ... article, “Digital mammographic density and breast cancer risk: ... methods,” demonstrates a strong connection between breast density ...
(Date:9/30/2014)... home surrounded by loved ones comes too late for ... change the process so that more patients may die ... the Frances Payne Bolton School of Nursing at Case ... million grant from the National Institute of Nursing Research ... Aggressiveness of End of Life Cancer Care," will contribute ...
Breaking Medicine News(10 mins):Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 2Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 3Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 4Health News:Arvixe Is Named Best VPS Hosting by MyServer2Go.com 2Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 2Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 3Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 4Health News:CWRU researchers receives $2.06 million to study how patients make end-of-life decisions 2
... Attention Deficit Hyperactivity Disorder, or ADHD, is widely recognized by ... in place. But as many as six percent of all ... Demonstrating a lack of refined motor skills, children with DCD ... staying organized at school. They appear to be uncoordinated ...
... , SUNDAY, April 3 (HealthDay News) -- There,s a ... women, but it depends on their body weight, researchers report. ... smokers who were not obese, but this strong association was ... study. Researchers analyzed data from 76,628 women, aged 50 ...
... test believe it is the most accurate yet in ... asbestos. Study results of this aptamer proteomic technology were ... April 2-6. In a blinded test performed under ... Research Network Biomarker Discovery Lab, the proteomic assay could ...
... NYU Langone Medical Center have investigated a novel protein ... can accurately identify proteins secreted from cancerous tumors caused ... American Association for Cancer Research 102nd Annual Meeting 2011 ... performed under the sponsorship of the National Cancer Institute,s ...
... Amanda Gardner HealthDay Reporter , SUNDAY, April 3 ... a new valve in a damaged heart is as good ... risk of stroke, researchers reported Sunday. Transcatheter ... in the heart via an artery in the leg or ...
... Reporter , SATURDAY, April 2 (HealthDay News) -- Men taking ... the risk of a heart attack or stroke, a small, ... 5 percent increase in the thickness of the large artery ... to the brain, the researchers from Emory University found. ...
Cached Medicine News:Health News:Clumsy kids who don't 'grow out of it' 2Health News:Study Links Smoking, Breast Cancer in Older Women 2Health News:Protein test detects early-stage, asbestos-related pulmonary cancer 2Health News:New test detects early-stage, asbestos-related pulmonary cancer 2Health News:Minimally Invasive Heart-Valve Procedure Shows Promise: Study 2Health News:Minimally Invasive Heart-Valve Procedure Shows Promise: Study 3Health News:Study Hints at Link Between Antidepressants and Heart Trouble 2Health News:Study Hints at Link Between Antidepressants and Heart Trouble 3
... A lower cost alternative to Equalizers, the ... transfers between two different vessel configurations. With the ... can be quickly and easily adjusted for test ... Ergonomic Design for Unparalleled Comfort Pick ...
... The Equalizer With 384 Well Plate ... the revolutionary features of the original Equalizerexpandable and ... autoclavable components, and in-lab calibration capabilities. In addition, ... tips down to 4.5mm for loading and accessing ...
Packaging: Set includes: Eight-channel pipette (10.8 mm with 0.5-5.0 μl capacity) 25 PrismStrip 96 tips with rack 2 FlexPlates with a holder...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
Medicine Products: